Cargando…
Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study
OBJECTIVE: Camrelizumab is a newly developed program-death receptor one inhibitor; the real-world evidence about its application in hepatocellular carcinoma (HCC) treatment is lacking. Therefore, this prospective, multi-center, real-world study evaluated the efficacy and safety of camrelizumab plus...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9378838/ https://www.ncbi.nlm.nih.gov/pubmed/35982962 http://dx.doi.org/10.3389/fonc.2022.816198 |
_version_ | 1784768597013299200 |
---|---|
author | You, Ran Xu, Qingyu Wang, Qi Zhang, Qingqiao Zhou, Weizhong Cao, Chi Huang, Xiangzhong Ji, Honghai Lv, Penghua Jiang, Hao Lu, You Jin, Yong Li, Yongjun Cheng, Long Wang, Weidong Xu, Hao Zhu, Xiaoli Yin, Guowen |
author_facet | You, Ran Xu, Qingyu Wang, Qi Zhang, Qingqiao Zhou, Weizhong Cao, Chi Huang, Xiangzhong Ji, Honghai Lv, Penghua Jiang, Hao Lu, You Jin, Yong Li, Yongjun Cheng, Long Wang, Weidong Xu, Hao Zhu, Xiaoli Yin, Guowen |
author_sort | You, Ran |
collection | PubMed |
description | OBJECTIVE: Camrelizumab is a newly developed program-death receptor one inhibitor; the real-world evidence about its application in hepatocellular carcinoma (HCC) treatment is lacking. Therefore, this prospective, multi-center, real-world study evaluated the efficacy and safety of camrelizumab plus transarterial chemoembolization (TACE) in treating intermediate-to-advanced HCC patients. METHODS: This study consecutively enrolled 101 intermediate to advanced HCC patients. All patients received camrelizumab-based treatment within 30 days of the perioperative period of the TACE operation. The primary outcome was progression-free survival (PFS), and the secondary effects were overall survival (OS), objective response rate (ORR), disease control rate (DCR), and AEs. RESULTS: Specifically, the median PFS was 9.7 (95% confidence interval: 7.4–12.0) months, with a 1-year PFS rate of 30.6%. Meanwhile, the median OS was not reached (NR) yet, with a 1-year OS rate of 61.9%. Besides, the CR, PR, SD, and PD rates were 12.8%, 44.9%, 29.5%, and 12.8%, respectively. The ORR and DCR were 57.7% and 87.2%, respectively. More cycles of camrelizumab were independently correlated with prolonged PFS (hazard ratio (HR): 0.415, P = 0.002), whereas longer intervals between camrelizumab administration and TACE were independently associated with unfavorable PFS (HR: 1.873, P = 0.032). The incidence of total AEs was 90.1%; most AEs were grade 1 (20.8%), grade 2 (28.7%) and grade 3 (37.6%), while only 3 (3.0%) patients had grade 4 AEs. CONCLUSION: The camrelizumab plus TACE regimen is effective and safe, indicating its potential to serve as a promising treatment choice for intermediate to advanced HCC patients. |
format | Online Article Text |
id | pubmed-9378838 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93788382022-08-17 Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study You, Ran Xu, Qingyu Wang, Qi Zhang, Qingqiao Zhou, Weizhong Cao, Chi Huang, Xiangzhong Ji, Honghai Lv, Penghua Jiang, Hao Lu, You Jin, Yong Li, Yongjun Cheng, Long Wang, Weidong Xu, Hao Zhu, Xiaoli Yin, Guowen Front Oncol Oncology OBJECTIVE: Camrelizumab is a newly developed program-death receptor one inhibitor; the real-world evidence about its application in hepatocellular carcinoma (HCC) treatment is lacking. Therefore, this prospective, multi-center, real-world study evaluated the efficacy and safety of camrelizumab plus transarterial chemoembolization (TACE) in treating intermediate-to-advanced HCC patients. METHODS: This study consecutively enrolled 101 intermediate to advanced HCC patients. All patients received camrelizumab-based treatment within 30 days of the perioperative period of the TACE operation. The primary outcome was progression-free survival (PFS), and the secondary effects were overall survival (OS), objective response rate (ORR), disease control rate (DCR), and AEs. RESULTS: Specifically, the median PFS was 9.7 (95% confidence interval: 7.4–12.0) months, with a 1-year PFS rate of 30.6%. Meanwhile, the median OS was not reached (NR) yet, with a 1-year OS rate of 61.9%. Besides, the CR, PR, SD, and PD rates were 12.8%, 44.9%, 29.5%, and 12.8%, respectively. The ORR and DCR were 57.7% and 87.2%, respectively. More cycles of camrelizumab were independently correlated with prolonged PFS (hazard ratio (HR): 0.415, P = 0.002), whereas longer intervals between camrelizumab administration and TACE were independently associated with unfavorable PFS (HR: 1.873, P = 0.032). The incidence of total AEs was 90.1%; most AEs were grade 1 (20.8%), grade 2 (28.7%) and grade 3 (37.6%), while only 3 (3.0%) patients had grade 4 AEs. CONCLUSION: The camrelizumab plus TACE regimen is effective and safe, indicating its potential to serve as a promising treatment choice for intermediate to advanced HCC patients. Frontiers Media S.A. 2022-08-02 /pmc/articles/PMC9378838/ /pubmed/35982962 http://dx.doi.org/10.3389/fonc.2022.816198 Text en Copyright © 2022 You, Xu, Wang, Zhang, Zhou, Cao, Huang, Ji, Lv, Jiang, Lu, Jin, Li, Cheng, Wang, Xu, Zhu and Yin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology You, Ran Xu, Qingyu Wang, Qi Zhang, Qingqiao Zhou, Weizhong Cao, Chi Huang, Xiangzhong Ji, Honghai Lv, Penghua Jiang, Hao Lu, You Jin, Yong Li, Yongjun Cheng, Long Wang, Weidong Xu, Hao Zhu, Xiaoli Yin, Guowen Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study |
title | Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study |
title_full | Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study |
title_fullStr | Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study |
title_full_unstemmed | Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study |
title_short | Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study |
title_sort | efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: a prospective, multi-center, real-world study |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9378838/ https://www.ncbi.nlm.nih.gov/pubmed/35982962 http://dx.doi.org/10.3389/fonc.2022.816198 |
work_keys_str_mv | AT youran efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy AT xuqingyu efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy AT wangqi efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy AT zhangqingqiao efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy AT zhouweizhong efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy AT caochi efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy AT huangxiangzhong efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy AT jihonghai efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy AT lvpenghua efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy AT jianghao efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy AT luyou efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy AT jinyong efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy AT liyongjun efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy AT chenglong efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy AT wangweidong efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy AT xuhao efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy AT zhuxiaoli efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy AT yinguowen efficacyandsafetyofcamrelizumabplustransarterialchemoembolizationinintermediatetoadvancedhepatocellularcarcinomapatientsaprospectivemulticenterrealworldstudy |